Clinical Trial Update: A Phase 3 Evaluation of Daclatasvir and Asunaprevir in Treatment-naive Subjects With Chronic Hepatitis C Genotype 1b Infection [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating the fixed-dose combination of daclatasvir and asunaprevir in treatment-naive adults with chronic hepatitis C genotype 1b has complete…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Asunaprevir (asunaprevir)
• Daklinza (Daclatasvir)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Hepatitis C | Phase 3 | Status: COMPLETED